作者
Scott Antonia,Augusto Villegas,Davey B. Daniel,David Vicente,Shuji Murakami,Rina Hui,Takayasu Kurata,Alberto Chiappori,Ki Hyeong Lee,Maike de Wit,Byoung Chul Cho,Maryam Bourhaba,Xavier Quantin,Takaaki Tokito,Tarek Mekhail,David Planchard,Young‐Chul Kim,Christos S. Karapetis,Sandrine Hiret,Gyula Ostoros,Kaoru Kubota,Jhanelle E. Gray,Luis Paz‐Ares,Javier de Castro,C. Faivre‐Finn,Martin Reck,Johan Vansteenkiste,David R. Spigel,Catherine Wadsworth,Giovanni Melillo,Maria Taboada,Phillip A. Dennis,Mustafa Özgüroğlu
摘要
An earlier analysis in this phase 3 trial showed that durvalumab significantly prolonged progression-free survival, as compared with placebo, among patients with stage III, unresectable non–small-cell lung cancer (NSCLC) who did not have disease progression after concurrent chemoradiotherapy. Here we report the results for the second primary end point of overall survival.
cdercder
昏睡的蟠桃
bc
诸葛御风
jenningseastera
椰子在长江送礼物
yizhouchang
Eve丶Paopaoxuan
卡卡西
期待未来的自己
TT
ahspark
pluto
科研助手6
大腚疯猪
YifanWang
xiaxiao
HEIKU
余味
冰魂
皖公网安备34019202002308
